Humacyte, Inc. (NASDAQ:HUMA) Given Consensus Recommendation of “Buy” by Brokerages
Humacyte, Inc. (NASDAQ:HUMA – Get Free Report) has been assigned a consensus rating of “Buy” from the eight research firms ...
Humacyte, Inc. Sued for Securities Law Violations – Investors Should Contact Levi ...
NEW YORK, NY / ACCESSWIRE / November 28, 2024 / If you suffered a loss on your Humacyte, Inc. (NASDAQ:HUMA) investment and want to learn about a ...
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel ...
New York, New York-- (Newsfile Corp. - November 28, 2024) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, ...
bovnews19 小时
What’s Causing Humacyte Inc (HUMA) Stock’s -51.65% Drop Over the Last Six Months?
On Wednesday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.4 which represents a decrease of $-0.03 or -0.68% from the prior close of $4.43. The stock opened at $4.44 and touched a low ...
Morningstar3 天
Humacyte, Inc. Class Action Lawsuit Alert: Johnson Fistel Announces Shareholders with ...
25, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Johnson Fistel, LLP announces that a class action lawsuit has commenced on behalf of investors of Humacyte, Inc. (NASDAQ: HUMA).
Yahoo Finance1 天
Humacyte, Inc. (HUMA)
DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable ...
Seeking Alpha29 天
Revisiting Humacyte
When I first analyzed Humacyte in October 2022, its stock was trading at ~$4.65 a share and prospects looked encouraging for its then dubbed human acellular vessel (HAV) platform candidates.
Humacyte首席执行官Laura Niklason购买价值7,978美元的股票
Humacyte, Inc.（纳斯达克股票代码：HUMA）的总裁、首席执行官兼董事Laura E. Niklason最近购买了1,797股公司普通股。这些股票的平均购买价格为每股4.44美元，总交易价值为7,978美元。此次交易后，Niklason直接持有243,851股。此外，她还通过The Niklason Living Trust和Ayabudge LLC等多个实体间接持有股份。
Humacyte董事Brady Dougan出售价值660万美元股份
根据最近的披露，Humacyte, Inc. (NASDAQ:HUMA)的董事Brady W. Dougan报告出售了他在公司的大量持股。这些交易发生在11月18日至11月20日的三天期间，共涉及出售150万股Humacyte普通股。
Yahoo Finance2 天
Humacyte, Inc. (HUMAW)
As of November 25 at 4:00 PM EST. Market Open. DURHAM, N.C., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally ...
bovnews2 天
Why Is Humacyte Inc (HUMA) Stock Lagging Behind -19.11% from Its 50-Day SMA?
On Monday, Humacyte Inc (HUMA) stock saw a decline, ending the day at $4.28 which represents a decrease of $-0.21 or -4.68% from the prior close of $4.49. The stock opened at $4.47 and touched a low ...
Insider Buyers At Humacyte Likely Disappointed With 17% Slide
Insiders who acquired US$775.1k worth of Humacyte, Inc.'s ( NASDAQ:HUMA ) stock at an average price of US$6.64 in ...